Seminars in Oncology
Volume 29, Issue 3 , Pages 222-230 , June 2002

Issues in clinical trial design for tumor marker studies

References 

  1. McLeod HL, Murray GI. Tumour markers of prognosis in colorectal cancer. Br J Cancer. 1999;79:191–203
  2. Hayes DF. Designing tumor marker studies: Will the results provide clinically useful information?. Arch Pathol Lab Med. 2000;124:952–954
  3. Hayes DF, Bast RC, Desch CE, et al.  Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996;88:1456–1466
  4. Carroll PR, Lee KL, Fuks ZY, et al.  Cancer of the prostate. In: ed 6.  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer, Principals and Practice of Oncology. Philadelphia: PA, Lippincott Williams & Wilkins; 2001;p. 1418–1480
  5. Clark GM. Prognostic and predictive factors for breast cancer. Breast Cancer. 1995;2:79–89
  6. Henderson C, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261–288
  7. Grem JL. 5-Fluorouracil: Forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299–313
  8. Johnston PG, Liang C-M, Henry S, et al.  Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissues. Cancer Res. 1991;51:6668–6676
  9. Johnston PG, Lenz HJ, Leichman CG, et al.  Thymidylate synthase gene and protein expression correlate and are associated with a response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995;55:1407–1412
  10. Johnston PG, Fisher ER, Rockette HE, et al.  The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994;12:2640–2647
  11. Edler D, Kressner U, Ragnhammar P, et al.  Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival. Clin Cancer Res. 2000;6:488–492
  12. Edler D, Hallstrom M, Johnston PG, et al.  Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin Cancer Res. 2000;6:1378–1384
  13. Lenz HJ, Danenberg KD, Leichman CG, et al.  p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res. 1998;4:1227–1234
  14. Paradiso A, Simone G, Petroni S, et al.  Thymidylate synthase and p53 primary tumor expression as predictive factors for advanced colorectal cancer patients. Br J Cancer. 2000;82:560–567
  15. Davies MM, Johnston PG, Kaur S, et al.  Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Cancer Res. 1999;5:325–328
  16. Cascinu S, Aschele C, Barni S, et al.  Thymidylate synthase protein exprssion in advanced colon cancer: Correlation with the site of matastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res. 1999;5:1996–1999
  17. Leichman CG, Lenz HJ, Leichman L, et al.  Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223–3229
  18. Lenz HJ, Danenberg KD, Leichman CG, et al.  p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res. 1998;4:1227–1234
  19. Salonga D, Danenberg KD, Johnson M, et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322–1327
  20. Pullarkat ST, Ghaderi V, Ingles SA, et al.  Human thymidylate synthase gene polymorphism determines response to 5-FU chemotherapy. Proc Am Soc. Clin Oncol. 2000;19:942; (abstr)
  21. George SL. Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol. 1996;14:1364–1370
  22. QUASAR Collaborative Group . Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomised trial. Lancet. 2000;355:1588–1596
  23. Watanabe T, Wu T-T, Catalano PJ, et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med. 2001;344:1196–1206
  24. Halling KC, French AJ, McDonnell SK, et al.  Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91:1295–1303
  25. Pajak TF, Clark GM, Sargent DJ, et al.  Statistical issues in tumor marker studies. Arch Pathol Lab Med. 2000;124:1011–1015
  26. Grignon D, Caplan R, Sarkar F, et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 86-10. J Natl Cancer Inst. 1997;89:158–165
  27. Ellenberg SS. Surrogate endpoints. Br J Cancer. 1993;68:457–459
  28. Buyse M, Thirion P, Carlson RW, et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000;356:373–378
  29. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994;69:979–985
  30. Janicke F, Thomssen CH, Pache L, et al.  Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In:  Schmitt M,  Graeff H,  Kindermann G editor. Prospects in Diagnosis and Treatment of Breast Cancer: Proceedings of the Joint International Symposium on Prospects in Diagnosis and Treatment of Breast Cancer, 10-11 November 1993. Munich. Amsterdam, the Netherlands: Elsevier Science; 1994;p. 207–218
  31. Thomssen C, Janicke F. Do we need better prognostic factors in node-negative breast cancer?. Eur J Cancer. 2000;36:293–298
  32. Peterson B, George SL. Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome. Control Clin Trials. 1993;14:511–522
  33. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is “statistically significant” clinically useful?. Breast Cancer Res Treat. 1998;52:305–319
  34. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York, NY: Wiley; 1987;

☆ Address reprint requests to Daniel Sargent, PhD, Director, Cancer Center Statistics, Mayo Clinic Cancer Center, Kahler 1-A, 200 1st St SW, Rochester, MN 55905.

PII: S0093-7754(02)50178-0

doi: 10.1053/sonc.2002.32898

Seminars in Oncology
Volume 29, Issue 3 , Pages 222-230 , June 2002

Article Tools

* Image Usage & Resolution